Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma

By Vuky Jacqueline   Isacson Christina   Fotoohi Mehran   Cruz Jason   Otero Henry   Picozzi Vincent   Malpass Thomas   Aboulafia David   Jacobs Andrew  

Investigational New Drugs, Vol. 24, Iss. 1, 2006-01 ,pp. : 85-88

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma

By Shaheen Philip   Stadler Walter   Elson Paul   Knox Jennifer   Winquist Eric   Bukowski Ronald  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 577-581

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

By Bruce Justine  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 794-802

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma

By Vaishampayan Ulka   Heilbrun Lance   Shields Anthony   Lawhorn-Crews Jawana   Baranowski Karen   Smith Daryn   Flaherty Lawrence  

Investigational New Drugs, Vol. 25, Iss. 1, 2007-02 ,pp. : 69-75

Springer Publishing Company

Access to resources Recommend Favorite

A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

By Garcia Jorge A.   Hudes Gary R.   Choueiri Toni K.   Stadler Walter M.   Wood Laura S.   Gurtler Jayne   Bhatia Shailender   Joshi Adarsh   Hozak Rebecca R.   Xu Yihuan   Schwartz Jonathan D.   Thompson John A.  

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1647-1655

Blackwell Publishing

Access to resources Recommend Favorite